Regulatory Filings • Feb 4, 2013
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 4 February 2013 07:00
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE Vaccine
Cytos Biotechnology AG / Key word(s): Research Update
04.02.2013 / 07:00
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE Vaccine
Schlieren (Zurich), Switzerland, February 4, 2013 – Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has been dosed in a Phase 1 clinical trial with an anti-IgE vaccine, which is being developed under a license agreement between both parties. Pfizer's anti-IgE vaccine is based on Cytos' VLP ('virus-like-particle') vaccine platform.
Christian Itin, Chairman and Chief Executive Officer of Cytos, comments: 'We are very pleased that Pfizer has advanced its anti-IgE vaccine to a Phase 1 clinical trial. This is an important milestone for the program and provides further evidence of the potential of Cytos' B-cell vaccine platform based on Q beta-derived virus like particles.'
Pfizer acquired world-wide exclusive rights to develop, manufacture and commercialize certain specified vaccines based on Cytos' VLP platform in 2009.
###
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: [email protected]
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: [email protected]
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
This foregoing press release may contain forward-looking statements that include words or phrases such as 'are intended for', 'are designed to', or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.
End of Corporate News
04.02.2013 This press release was distributed by EQS CORPORATE COMMUNICATIONS.
www.eqs.com – news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Swiss Security Number: | – |
| Listed: | Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX |
| End of News | EquityStory AG News-Service |
| - - - |
| 200410 04.02.2013 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.